The KRAS/BRAF/PIK3CA Array provides rapid detection of mutations within KRAS, BRAF and PIK3CA genes, to aid in the selection of patients for appropriate treatment of metastatic colorectal cancer. Despite recent therapeutic advances, the prognosis for patients with metastatic CRC (mCRC) remains poor. Early treatment is therefore critical. This array allows the clinician to correctly select appropriate patients for anti-EGFR therapy, thereby maximising drug efficacy and minimising adverse side effects to the patient. Mutations in the KRAS gene are known to disrupt the EGFR pathway, rendering anti-EGFR therapy ineffective. Presence of KRAS mutations accounts for approximately 35-45% of non-responsive patients. Oncogenic mutations in genes encoding key downstream effectors within the EGFR-signalling pathways may also be responsible for resistance to EGFR-targeted MoAbs.
Key Benefits • Streamlined workflow – Protocol and reagents are optimised for the molecular laboratory • Compatible with a broad range of genomic DNA input and type: o Cell lines o FFPE tissue o Fresh/frozen tissue
• Detection of 1% mutant in a background of wildtype genomic DNA • Single DNA sample only required • Single reaction multiplex PCR coupled to a biochip provides greater mutation coverage of the three genes (KRAS, BRAF and PIK3CA) • Turnaround time of three hours
Write a review
Sharing your experience will help scientists like you. Achieve Reviewer Status and Win an iPad 3 (All reviews published will be entered into the next drawing on January 30th 2014).